BEAM - Company ID 0001745999
The table below shows Beam Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $31.74M | $9.70M | $8.47M | $7.47M | $14.27M | $11.77M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $104.52M | $109.77M | $101.76M | $98.82M | $94.26M | $87.04M |
Beam Therapeutics Inc. reported annual revenue of $139.74M for fiscal year 2025. That is up 120.0% from $63.52M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $18.00K (FY 2019) to $139.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $34.43M |
| $26.74M |
| $26.86M |
| $27.94M |
| $26.52M |
| $29.63M |
| Operating income | -$107.22M | -$126.81M | -$120.15M | -$119.29M | -$106.50M | -$104.89M |
| Income tax | $0.00 | - | - | $0.00 | - | $39.00K |
| Net income | -$94.32M | -$112.73M | -$102.29M | -$108.33M | -$96.67M | -$91.05M |
| EPS (diluted) | -$0.91 | -$1.10 | -$1.00 | -$1.23 | -$1.17 | -$1.11 |